Evidence map›Paper›PMID 42809437›Full record

ArticleSTAR protocols2026

Protocol for quantification of AAV-CRISPR-mediated hepatic gene editing in mice.

Kelsey E Jarrett, Rodrigo Baltazar-Nunez, Chloe Anne Borja, Precious Juvie Calderon, Rochelle W Lai, Angela Cheng, Manasvi Paudel, Gabriella E Rubert, Anthony Suberski, Owen K Traina and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kelsey E JarrettDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: kelseyjarrett@g.ucla.edu.
Rodrigo Baltazar-NunezDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Chloe Anne BorjaDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Precious Juvie CalderonDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Rochelle W LaiDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Angela ChengDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Manasvi PaudelDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Gabriella E RubertDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Anthony SuberskiDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Owen K TrainaDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sunny Y CaiDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kalyani SrikanthDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
William R LagorDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Elizabeth J TarlingDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Thomas Q de Aguiar VallimDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: tvallim@mednet.ucla.edu.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The impact of estrogen receptor alpha on cardiomyocellular metabolism and healthU54HL170326 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Andrea L Hevener · 2023 to 2026
$7.5M
Targeting the gut-liver axis in cardiovascular diseaseR01HL163908 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeth Joanna Tarling, Thomas A Vallim · 2023 to 2026
$2.9M
Post-transcriptional regulation of LDLRR01HL174008 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeth Joanna Tarling, Thomas A Vallim · 2024 to 2026
$2.5M
ATP Binding Cassette Transporters in Health and DiseaseR01DK128952 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARLING, ELIZABETH JOANNA, VALLIM, THOMAS A · 2021 to 2024
$2.4M
Novel FXR-dependent Molecular Mechanisms in the Regulation of Liver MetabolismR01DK118064 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EDWARDS, PETER A, VALLIM, THOMAS A · 2019 to 2022
$2.1M
Bile acid-mediated control of lipid absorption and fatty liver diseaseR01DK138340 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Thomas A Vallim · 2024 to 2026
$1.9M
Novel Post-Transcriptional Regulators of Lipid MetabolismR01DK112119 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VALLIM, THOMAS A · 2017 to 2020
$1.7M
Role of Bile Acids in Time-Restricted FeedingK08DK146180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Alvin P Chan · 2026 to 2026
$171k
Female protection from MASLD via bile acid regulation of cholesterol levelsK01DK146204 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Kelsey E Jarrett · 2026 to 2026
$168k
NCATS NIH HHS UL1 TR001881NHLBI NIH HHS R01 HL163908NHLBI NIH HHS R01 HL174008NHLBI NIH HHS U54 HL170326NIDDK NIH HHS K01 DK146204NIDDK NIH HHS K08 DK146180NIDDK NIH HHS R01 DK112119NIDDK NIH HHS R01 DK118064NIDDK NIH HHS R01 DK128952NIDDK NIH HHS R01 DK138340
6 · The paper itself

Abstract

Adeno associated viral (AAV) delivery of CRISPR-Cas9 enables efficient, targeted hepatic gene disruption composed of both small insertions and deletions (INDELs) and larger DNA structural variants (DNA-SVs), which are difficult to quantify. Here, we present a protocol for quantifying AAV-CRISPR-mediated gene editing in mice. We describe guide RNA (gRNA) design, plasmid cloning, delivery of AAV-CRISPR to the liver, and execution of liver DNA-editing analysis. This protocol enables quantification of INDELs and DNA-SVs, allowing for validation of gene disruption. For complete details on the use and execution of this protocol, please refer to Chan et al.

Indexed as

CRISPRMetabolismMolecular Biology

Identifiers

PMID42809437
PMCPMC13654526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.